

# WHAT'S *Stirring?* at LCC

**Ross Goodyear**

**Deputy Team  
Leader**



**Bailey Gill**

**Business  
Development  
Specialist**

## **LCC Journey:**

Started in the production lab validating new chemistry and fulfilling custom synthesis orders before moving to LCC's Parallel Synthesis Lab (PSL) where I mainly work on our enantiopair electrophilic warhead collection.

## **Favourite part of your role?**

My favourite part is probably starting a new project. I always like reading about the new chemistry that I'll be doing, particularly to find out why that chemistry is important for that client and learning any new techniques that I might start to work with. Finishing a project is also a pretty good feeling!

## **Can you tell us about a recent project you were working on?**

So LCC have an enantiopair acrylamide fragment set and recently, we decided to

expand this. Making use of our PSL, we were able to increase our output and validate the transformation onto many different starting materials and double the amount of enantiopairs we can offer.

## **Any particular challenges that you faced during this project?**

Moving away from traditional, hands-on chemistry and towards an automated approach was challenging at first! However, it was interesting to see how we could adapt the chemistry to integrate it into our automated workflow and how we can develop the methodologies going forward.

## **What impact do you think this project will have on LCC?**

This was one of the first projects we did on our automated systems and the things we've learned throughout the project will form the basis for the development of new chemistries. This was already a big jump for us but I believe the next jumps could be 2-3 times the size of this one.

We're going from strength to strength!

## **What impact do you think this project will have on the drug discovery world?**

The drug discovery world are increasingly moving towards screening both enantiomers in their high-throughput assays. If we can use this project to be able to supply more novel, diverse and of course, chiral enantiopairs then it's going to massively help with their screening efforts and also cut down enormously on the time it takes to follow-on from a hit after they get one!